FDMT | tickerfilter.com

Fundamental analysis

15%

Profitability 18%

Dept financing 2%

Liquidity 75%

Performance 0%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-1.19%

1 Month

-22.53%

3 Months

-46.99%

6 Months

-72.35%

1 Year

-72.66%

2 Year

-73.09%

Key data

Stock price

$5.74

P/E Ratio

-7.10

DAY RANGE

$5.59 - $5.78

EPS

-$2.31

52 WEEK RANGE

$5.88 - $36.25

52 WEEK CHANGE

-$72.35

MARKET CAP

780.064 M

YIELD

N/A

SHARES OUTSTANDING

51.970 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

11/07/2024

BETA

1.61

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,612,478

AVERAGE 30 VOLUME

$1,004,988

Company detail

CEO: David H. Kirn
Region: US
Website: 4dmoleculartherapeutics.com
Employees: 120
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa, choroideremia, and 4 D-310.

FDMT - 4D Molecular Therapeutics, Inc.